20 results about "Uric acid transport" patented technology

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

The invention provides a dihydrofuro-indole compound with a structure as shown in a formula I, or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritide thereof, and application of the dihydrofuro-indole compound or the derivative thereof, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof, or the prodrug molecule thereof, or the deuteride thereof, or the tritide thereof. The dihydrofuro-indole compound or the derivative thereof provided by the invention is a compound with a novel structure, and the compound has relatively good inhibitory activity on urate oxidase and urate transporter protein, realizes XOR / URAT1 dual inhibition, has a good uric acid reducing effect, is good in safety, has a very good pharmacokinetic property, and can be used for preparing a medicine for treating uric acid. The compound is high in druggability, can be used for preparing uric acid reducing medicines, and is used for preventing and / or treating gout or hyperuricemia. # imgabs0 #

The embodiment of the invention discloses a uric acid reducing plant extract composition and a preparation method thereof, relates to the technical field of composite compositions, and aims to develop a composite plant extract composition with a uric acid reducing function and an excellent taste so as to meet market requirements. The uric acid-reducing plant extract composition comprises a mixed solution composed of turnip liquid and roxburgh rose primary pulp in a volume ratio of (1-3): (0.5-1.5), the mass volume ratio of the erythritol to the mixed solution is 5%-7%, the mass volume ratio of the citric acid to the mixed solution is 0.1%-0.4%, and the mass volume ratio of the compound stabilizer to the mixed solution is 0.03%-0.09%. The plant extract composition for reducing uric acid makes up the vacancy that no plant extract composition for reducing uric acid exists in the market, and synthesis-excretion dual-path regulation is realized by inhibiting xanthine oxidase (XOD) through turnip alkaloid and regulating urate transporter (ABCG-2 through rosa roxburghii tratt polyphenol, so that the effect of reducing uric acid is achieved.

The invention relates to the technical field of medicines, in particular to application of ginsenoside in preparation of medicines for improving kidney inflammation and enhancing uric acid excretion. It is found for the first time that ginsenoside Rg2 can reduce systematic and kidney inflammatory reactions by reducing expression levels of inflammatory factors LPS, TNF-alpha and IL-1beta; by down-regulating the expression level of fibrosis marker molecules alpha-SMA and Smad3, the effect of improving HUA-related kidney inflammation and fibrosis is achieved; by up-regulating the expression levels of uric acid transporters OAT1, OAT3 and ABCG2, the active transport and excretion ability of the kidney to uric acid is enhanced. The discovery can generate great influence on research and treatment of relieving hyperuricemia, and has clinical practical value.

The invention discloses an application of Kluyveromyces marxianus metabolite in preparation of drugs for reducing uric acid, protecting kidney and protecting intestinal tracts, and belongs to the technical field of medicines. The invention provides an oral composition / preparation which takes a Kluyveromyces marxianus fermentation metabolite as an effective component, and by inhibiting the activity of a purine metabolism key enzyme, regulating a kidney / intestinal uric acid transporter and remodeling the intestinal microecology, the effects of reducing uric acid and synchronously protecting the kidney and the intestine are realized, and the problems of single target spot, toxic and side effects, limitation on long-term medication and the like of the existing medicine are solved. The metabolite can significantly reduce serum uric acid, can protect kidney and intestinal functions, and realizes multiple effects of reducing uric acid, protecting kidney and protecting intestines. Compared with a single effect of an existing medicine, the kluyveromyces marxianus metabolite shows a more comprehensive treatment effect through regulation of intestinal flora, inhibition of xanthine oxidase and regulation and control of uric acid transporter.

The invention provides an application of a paederia scandens extract PSMF rich in flavonoid compounds in preparation of a product for reducing uric acid. Animal experiment research finds that the PSMF intervenes and relieves weight loss and food intake reduction of a mouse with hyperuricemia, and meanwhile, the decrease of liver and kidney indexes is reversed. In addition, the PSMF also significantly reduces the levels of serum uric acid, xanthine oxidase, adenosine deaminase, creatinine, blood urea nitrogen and the like of hyperuricemia mice, inhibits inflammatory response, and protects liver and kidney injury. And finally, the PSMF improves in-vivo uric acid homeostasis by regulating the expression of the uric acid synthesis gene and the uric acid transporter gene. Results show that PSMF intervention has an effect of regulating uric acid homeostasis, has a good treatment effect on hyperuricemia, and is expected to be used as a natural dietary supplement for treating and preventing hyperuricemia.

The invention discloses application of taxifolin in preparation of a product for inhibiting expression of a urate transporter, and relates to the technical field of biological medicines. The invention also provides an application of taxifolin in preparation of a product for promoting uric acid excretion and an application of taxifolin in preparation of a product for protecting human renal epithelial cells. The research finds that taxifolin has the effect of protecting human renal epithelial cells and can play a role in promoting uric acid excretion by regulating URAT1. The taxifolin not only has a good URAT1 regulating effect, but also has good safety, and compared with other similar URAT1 inhibitors, the taxifolin has good safety, protects human kidney epithelial cells, and has good application value.

The present invention provides a dihydrofuroindole compound having a structure as represented by formula I or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritide thereof, and a use thereof. The dihydrofuroindole compound or the derivative thereof provided by the present invention is a compound having a novel structure. The compound has good inhibitory activity against both urate oxidase and a urate transporter, is an XOR / URAT1 dual inhibitor, has a good urate-lowering effect, good safety, good pharmacokinetic properties, and high druggability, can be used for preparing a urate-lowering medicament, and can be used for preventing and / or treating gout or hyperuricemia.

The invention provides a theaflavin composition for preventing and treating hyperuricemia as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a chicory extract, a hovenia dulcis thunb extract, a semen plantaginis extract, a poria cocos extract, a pericarpium citri reticulatae extract and a corn stigma extract. The theaflavin, the cichorium intybus extract, the hovenia dulcis thunb extract and the semen plantaginis extract are used for inhibiting the activity of xanthine oxidase and regulating the function of uric acid transporter to realize bidirectional regulation of uric acid generation and excretion aiming at the diseases of excessive uric acid generation and excretion reduction; the poria cocos extract and the pericarpium citri reticulatae extract fundamentally improve internal environment disorder through transportation and transformation functions of the spleen and the stomach, reduce generation of phlegm dampness and stasis and create good body conditions for uric acid metabolism; the corn stigma extract guides all the medicines to directly reach the disease site, enhances the concentration and action efficiency of the medicines in excretion organs, accurately positions the urinary system, and forms a multi-target all-directional synergistic treatment system of treating symptoms, treating root causes and inducing meridians.

The invention belongs to the technical field of extraction and separation, and particularly relates to a preparation method and application of rhizoma polygonati total flavonoids. According to the preparation method provided by the invention, the extraction rate of the total flavonoids of the rhizoma polygonati can be increased, 324 flavonoid components are analyzed and identified in the extracted flavonoid extract and mainly contain flavones, flavanone, flavonol, isoflavone and other flavonoids, the content of effective components is high, the preparation process is simple and controllable, and the method is suitable for large-scale production; the total flavonoids of polygonatum sibiricum provided by the invention can effectively relieve oxidative stress of HK-2 cells induced by uric acid and improve the oxidation resistance of the cells, so that the toxic effect of a hyperuricemia environment on kidney cells is relieved; and further research shows that by adjusting the expression of a kidney uric acid transporter URAT1, uric acid reabsorption can be reduced, kidney uric acid excretion can be promoted, and the compound has a good application prospect in preparation of uric acid lowering drugs, anti-hyperuricemia drugs and the like.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

The invention provides an indolo saturated ring compound with a structure as shown in a formula I or a formula II, or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, and an application of the indolo saturated ring compound or the derivative thereof, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof, or the prodrug molecule thereof, or the deuteride thereof, or the tritium thereof. The indolo saturated ring compound or the derivative thereof provided by the invention is a compound with a novel structure, and the compound has relatively good inhibitory activity on urate oxidase and urate transporter, realizes XOR / URAT1 dual inhibition, has a good uric acid reducing effect, is good in safety, has a very good pharmacokinetic property, and can be used for preparing a medicine for treating uric acid. The compound is high in druggability, can be used for preparing uric acid reducing medicines, and is used for preventing and / or treating gout or hyperuricemia.

The application provides an indole saturated ring compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium compound thereof, and an application thereof. The indole saturated ring compound or the derivative thereof provided by the application is a novel compound, the compound has good inhibitory activity on uric acid oxidase and uric acid transporter, is XOR / URAT1 dual inhibition, has good uric acid reducing effect, has good safety, has good pharmacokinetics, has high drug property, and can be used for preparing a uric acid reducing drug and used for preventing and / or treating gout or hyperuricemia.

Provided in the present invention are an oxazolo- or thiazolo-indole compound having a structure as represented by formula I or a derivative thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a prodrug molecule thereof, a deuterated compound thereof or a tritiated compound thereof, and the use thereof. The oxazolo or thiazolo-indole compound or derivative thereof provided in the present invention is a compound with a new structure. The compound exhibits a relatively good inhibitory activity against both xanthine oxidases and uric acid transporters, XOR / URAT1 dual inhibition, and good uric acid-lowering effects. Moreover, the compound has high safety, desirable pharmacokinetic properties, and high druggability, and can be used in the preparation of uric acid-lowering drugs for preventing and / or treating gout or hyperuricemia.

The present invention provides an indole-fused saturated ring compound or a derivative thereof having the structure shown in Formula I or Formula II, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuterated compound thereof, or a tritiated compound thereof, and a use thereof. The indole-fused saturated ring compound or derivative thereof provided by the present invention are a class of structurally novel compounds. Said class of compounds has good inhibitory activity against both uricase and urate transporters, is a dual XOR / URAT1 inhibitor, and has a strong uric acid-lowering effect, good safety, favorable pharmacokinetic properties, and high druggability. Said compounds can be used for the preparation of uric acid-lowering drugs and for preventing and / or treating gout or hyperuricemia.

The invention provides an oxazole or thiazoloindole compound with a structure as shown in a formula I, or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritide thereof, and an application of the oxazole or thiazoloindole compound, or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritide thereof. The oxazole or thiazoloindole compound or the derivative thereof provided by the invention is a compound with a novel structure, and the compound has relatively good inhibitory activity on xanthine oxidase and uric acid transporter protein, realizes XOR / URAT1 dual inhibition, has a good uric acid reducing effect, is good in safety, has a very good pharmacokinetic property, and can be used for preparing a medicine for treating uric acid. The compound is high in druggability, can be used for preparing uric acid reducing medicines, and is used for preventing and / or treating gout or hyperuricemia.

The application provides an oxazole or thiazole indole compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium compound thereof, and an application thereof. The oxazole or thiazole indole compound or the derivative thereof provided by the application is a novel compound, the compound has good inhibitory activity on xanthine oxidase and uric acid transporter, is XOR / URAT1 dual inhibition, has good uric acid-lowering effect, has good safety, has good pharmacokinetic properties, has high drugability, and can be used for preparing a uric acid-lowering drug and used for preventing and / or treating gout or hyperuricemia.

The invention relates to the technical field of microorganisms, and discloses a plant lactobacillus CQZC202402 and application of the plant lactobacillus CQZC202402 in reducing uric acid. The plant lactobacillus CQZC202402 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.31105, and the preservation time is June 27, 2024. According to the plant lactobacillus CQZC202402, the content of blood uric acid and creatinine and the level of inflammatory factors can be reduced, the activity of adenosine deaminase and xanthine oxidase in the liver is reduced, and the expression of uric acid transport related genes OAT1, UAT and ABCG2 is remarkably up-regulated, that is, the plant lactobacillus CQZC202402 can relieve hyperuricemia caused by abnormal diet and excretion.